AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036

AB Science SA (AB) announced the issuance of a Canadian patent protecting the composition of matter for AB8939, a novel microtubule destabilizer being evaluated in Phase 1 clinical trials for acute myeloid leukemia (AML), until 2036. This Canadian patent completes intellectual property coverage for AB8939 across key geographic markets, including Europe, the US, and China, and strengthens the overall protection for its clinical development program. AB8939 has also received orphan drug designation for AML from both the EMA and the FDA, providing market exclusivity in Europe and the United States.

Analysis

AB Science SA has significantly de-risked the future commercialization of its acute myeloid leukemia (AML) candidate, AB8939, by securing a Canadian patent (CA 2975644) that protects its composition of matter until 2036. This development is crucial as it completes the intellectual property (IP) footprint for AB8939 across all key global markets, including Europe, the USA, China, Japan, and South Korea. AB8939, a novel microtubule destabilizer, is currently in Phase 1 clinical trials, having completed initial dose-finding studies; the next clinical step involves evaluating its combination with Vidaza® (azacitidine). The compound's market protection is further solidified by orphan drug designations from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), granting 10 and 7 years of market exclusivity post-approval in Europe and the US, respectively, alongside 8 years of regulatory data protection in Canada. AB Science also disclosed a pending secondary medical use patent application aiming to extend protection to 2044 for specific AML sub-populations, potentially enhancing the drug's long-term value proposition. The company's 100% ownership of AB8939's IP underscores its full control over this promising asset targeting both cancer cells and cancer stem cells.

Key Decisions for Investors

• Investors should view the comprehensive global patent protection for AB8939, now including Canada and extending to 2036, as a significant enhancement to the drug's long-term commercial viability and a reduction in IP-related risks.
• Monitor upcoming clinical trial data closely, particularly the results from the Phase 1 study of AB8939 in combination with Vidaza®, as successful outcomes will be key catalysts for value appreciation.
• While the strengthened IP and orphan drug designations are positive, factor in the early stage of AB8939's clinical development (Phase 1) and the inherent risks associated with biopharmaceutical R&D when assessing AB Science's valuation.
• Consider the potential for extended market exclusivity until 2044 if the secondary medical use patent is granted, which could further bolster the asset's value, especially for targeted AML patient sub-populations.